Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed multiple myeloma patients from a recent economic analysis of Denosumab v Zoledronic Acid in Multiple Myeloma at the 2017 Lymphoma and Myeloma meeting in New York.
Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma
